The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications.
Després
J P
JP
Lipid Research Center, CHUL Research Center, Ste-Foy, Canada.
Lemieux
S
S
Lamarche
B
B
Prud'homme
D
D
Moorjani
S
S
Brun
L D
LD
Gagné
C
C
Lupien
P J
PJ
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000235:genetics / Q000503:physiopathology; D005277:Fenfluramine / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000235:genetics / Q000503:physiopathology; D007333:Insulin Resistance / Q000235:genetics / Q000502:physiology*; D009765:Obesity / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D012307:Risk Factors; D013577:Syndrome
D005277:Fenfluramine